Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Assets: 2011-2025

Historic Other Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to $9.3 million.

  • Iovance Biotherapeutics' Other Non-Current Assets was N/A to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year change of. This contributed to the annual value of $6.4 million for FY2024, which is 90.43% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Other Non-Current Assets stood at $9.3 million for Q3 2025, which was down 10.15% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Other Non-Current Assets ranged from a high of $66.4 million in Q2 2023 and a low of $5.8 million during Q1 2025.
  • Over the past 3 years, Iovance Biotherapeutics' median Other Non-Current Assets value was $9.3 million (recorded in 2025), while the average stood at $27.1 million.
  • Data for Iovance Biotherapeutics' Other Non-Current Assets shows a maximum YoY tumbled of 90.43% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Other Non-Current Assets (Quarterly) stood at $66.4 million in 2023, then slumped by 90.43% to $6.4 million in 2024, then declined by 9.46% to $9.3 million in 2025.
  • Its Other Non-Current Assets was $9.3 million in Q3 2025, compared to $10.3 million in Q2 2025 and $5.8 million in Q1 2025.